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Abstract (387 words) 
Background:  
Eukaryotic chromosomal ends are linear and are protected by nucleoprotein complexes 
known as telomeres.  The complex structural anatomy and the diverse functions of telomeres 55 
as well as the unique reverse transcriptase enzyme, telomerase that maintains telomeres are 
under intensive scientific scrutiny. Both are involved in many human diseases including 
cancer, but also in ageing and chronic disease such as diabetes. Their intricate involvement in 
many cellular processes and pathways is being dynamically deciphered in many organs 
including the endometrium. This review summarises our current knowledge on the topic of 60 
telomeres and telomerase and their potential role in providing plausible explanations for 
endometrial aberrations related to common gynaecological pathologies.  
Objective and rationale:  
This review outlines the recent major findings in telomere and telomerase functions in the 
context of endometrial biology. It highlights the contemporary discoveries in hormonal 65 
regulation, normal endometrial regeneration, stem cells and common gynaecological diseases 
such as endometriosis, infertility, recurrent reproductive failure and endometrial cancer.  
Search methods: 
Authors carried out systematic PubMed (Medline) and Ovid searches using the key words: 
telomerase, telomeres, telomere length, hTERT, TERC, with endometrium, hormonal 70 
regulation, endometrial stem/progenitor cells, endometrial regeneration, endometriosis, 
recurrent miscarriage, infertility, endometrial hyperplasia, endometrial cancer, and uterine 
cancer. Publications used in this review date from 1995 until 31st June 2016.  
Outcomes:  
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The human endometrium is a unique somatic organ, which displays dynamic telomerase 75 
activity related to the menstrual cycle. Telomerase is implicated in almost all endometrial 
pathologies and appears to be crucial to endometrial stem cells. In particular, it is vital for 
normal endometrial regeneration, providing a distinct route to formulate possible curative, 
non-hormonal therapies to treat chronic endometrial conditions. Furthermore, our current 
understanding of telomere maintenance in endometrial cancer is incomplete. Data derived 80 
from other malignancies on the role of telomerase in carcinogenesis cannot be extrapolated to 
endometrial cancer because unlike in other cancers, telomerase activity is already present in 
proliferating healthy endometrial cells.  
Wider implications:  
Since telomerase is pivotal to endometrial regeneration, further studies elucidating the role of 85 
telomeres, telomerase, their associated proteins and their regulation in normal endometrial 
regeneration as well as their role in endometrial pathologies are essential. This approach may 
allow future development of novel treatment strategies that are not only non-hormonal but 
potentially curative. 
 90 
Key words: endometrium, telomerase, telomere, stem cells, endometriosis, endometrial 
cancer, infertility, recurrent miscarriage, progesterone, estrogen 
 
Introduction 
All eukaryotic chromosomal ends consist of specialised heterochromatin nucleoprotein 95 
complexes, termed telomeres containing repeated nucleotide sequences ((TTAGGG)n) and 
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associated specific proteins (Blackburn and Gall 1978). The intact telomeres prevent the 
chromosomal ends from being recognised as DNA strand break and protects the loss of 
genomic DNA as well as end-to end fusion and degradation of chromosomes. Telomeric 
DNA is lost with each round of DNA replication (Lundblad 2012; Olovnikov 1971; Watson 100 
1971) and shortening of telomeres beyond a critical length results in a permanent cell cycle 
arrest. This is due to initiation of sustained DNA damage signalling, resulting in activation of 
either senescence or apoptosis pathways (Blackburn and Gall 1978; Blackburn, Epel, and Lin 
2015). Telomere shortening and telomerase dysfunction are therefore implicated as universal 
features of cellular senescence, ageing as well as age related decrease in tissue regeneration 105 
and lifespan restriction in long lived mammals (Djojosubroto et al. 2003; Mikhelson and 
Gamaley 2012).  
The action of the reverse transcriptase enzyme telomerase is the main mechanism that 
counteracts telomere shortening in cells. Human cells such as embryonic stem cells, germline 
cells and cancer cells with unlimited replicative capacity express high levels of telomerase 110 
activity (TA) which maintains and elongates telomeres; compensating for telomeric erosion 
(Counter et al. 1992; Meena, Rudolph, and Gunes 2015; Yang and Huang 2014). In contrast, 
adult stem and progenitor cells (SPCs) have the potential to up-regulate telomerase but these 
cells also undergo telomere shortening with age (Hiyama and Hiyama 2007; Rane et al. 2016; 
Flores et al. 2008). Most human somatic cells do not express significant levels of TA 115 
(Opresko and Shay 2016) and age related telomere shortening is commonly described in 
many human proliferative tissues (Djojosubroto et al. 2003) while telomere shortening in 
post-mitotic tissues is negligible (Benetos et al. 2011). . Therefore, most work on the 
functional relevance of telomerase is confined to the aforementioned specialised cells that 
express telomerase, such as cancer and stem cells.  120 
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The human endometrium is a unique organ in terms of regeneration and ageing. It is a 
dynamic somatic tissue; undergoing repetitive monthly cycles of growth, differentiation, 
shedding, and regeneration throughout a woman’s reproductive life. This cycle of 
endometrial cell proliferation and growth is regulated by ovarian steroid hormones 
(Hapangama, Kamal, and Bulmer 2015). Every month, the endometrium grows from 1 mm in 125 
thickness at the end of the menstrual shedding, to a 15mm in thickness measured in the mid-
secretory phase of the cycle (Dallenbach-Hellweg 2010),  thus endometrial regeneration 
capacity is unparalleled amongst other adult tissues. At the menopause, with the cessation of 
ovarian steroid hormone synthesis, the endometrium becomes proliferatively quiescent. 
However, a fully functional endometrium can be regenerated from the remaining thin post-130 
menopausal endometrium with the provision of exogenous ovarian steroid hormones 
(Paulson et al. 2002). Thus, it is the only female reproductive organ not showing irreversible 
age-related changes. Although being a somatic organ, endometrium expresses dynamic TA 
associated with the menstrual cycle. Therefore, the apparent endometrial age-defiance might 
include a physiological regulation of telomeres and telomerase distinct from other human 135 
tissues.  
 
This review focuses particularly on recent findings in endometrial telomere and telomerase 
biology in the context of the inexhaustible proliferative and regenerative capacity of the 
human endometrium. This may provide an explanation for the seemingly eternal 140 
‘youthfulness’ retained by the endometrium throughout a woman’s life when compared with 
other female reproductive organs. Furthermore, there is mounting evidence that telomerase 
and telomere dysfunctions might play important roles in endometrial pathologies. 
Method:  
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We performed systematic PubMed (Medline) and Ovid searches using key words: 145 
telomerase, telomeres, telomere length (TL), telomerase reverse transcriptase (TERT), 
telomeric RNA component (TERC), with endometrium, endometrial stem/progenitor cells, 
endometrial regeneration, endometriosis, recurrent miscarriage, infertility, endometrial 
hyperplasia, endometrial cancer, and uterine cancer. All studies investigating telomerase, 
telomere biology in endometrium in women, animals and respective cell lines, either primary 150 
cells or tissue explants in culture published from 1995 until 30th July 2016 were considered. 
Further manuscripts published before 1995 were also reviewed for specific topic areas and 
are included as appropriate. 
 
  155 
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Telomeres: 
Structure  
The mammalian telomere complex consists of a tandemly repeated telomeric DNA sequence 
d(TTAGGG)n and its complementary strand. This is, followed by a short (35-600 nucleotide) 
single stranded 3’ guanosine-rich protruding overhang; known asthe G-tail (Royale 2006; 160 
Blackburn, Epel, and Lin 2015). Telomeres are associated with a complex of six well 
described shelterin proteins; Telomeric Repeat Factor 1 and 2 (TRF1, TRF2), 
Repressor/Activator Protein I (RAP1, encoded by TERF2IP gene), TRF1-Interacting Nuclear 
Protein 2 (TIN2), Tripeptidyl Peptidase I (TPP1) and Protection of Telomeres I (POT1). 
TRF1, and TRF2 bind directly to the double stranded telomeric sequence, and POT1 binds 165 
the single stranded overhang, these proteins are therefore telomere DNA binding proteins. 
They interact with and bind to the remaining 3 shelterin proteins: TIN2 to TRF1, RAP1 to 
TRF2 and TPP1 to POT1.   
The single stranded overhang forms a D-loop (displacement) (Griffith et al. 1999) that 
prevents the access of telomerase outside of late S-phase when the overhang becomes 170 
accessible (Figure 1A) (de Lange 2005; Palm and de Lange 2008; Shay 2016). In addition, 
the whole telomere forms a large duplex structure (T-loop) via the strand invasion from the 3’ 
single stranded overhang (Griffith et al. 1999; Blackburn et al. 2000) providing proper 
telomere capping. The T-loop size is believed to be proportional to the length of the 
respective telomere (Cimino-Reale et al. 2001). Thus, in addition to telomere shortening the 175 
dysfunction of telomere capping can also initiate a DNA damage response (DDR) (Yoo and 
Chung 2011; Bodvarsdottir et al. 2012; Griffith et al. 1999).  
The shelterin complex is ubiquitously expressed and remains associated to telomeres during 
the cell cycle (Takai et al. 2011; Royale 2006). In addition to the 6 shelterin proteins there are 
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various additional proteins (e.g. NBS1/MRE11/Rad50, tankyrase, PinX1, Ku) located at the 180 
telomere that are involved in DNA damage response and repair processes but also have non-
telomeric functions (Kuimov 2004; De Boeck et al. 2009).  
Telomere Shortening 
Telomere shortening with age is a general observation in human proliferating tissues.  In cell 
culture, with each cell division, about 20- 50 base pairs (bp) of telomeric DNA is lost due to 185 
“the end replication problem” (Olovnikov 1973) (Watson 1972). This term describes the fact 
that DNA polymerases can only synthesise in 5’-3’ direction and thus can only synthesise the 
leading DNA strand un-interrupted. The lagging strand is synthesised by a series of Okazaki 
fragments which requires the help of short RNA primers and that are finally ligated together 
by ligases. However, at the very end of the lagging strand, the terminal RNA primer is 190 
removed resulting in the 3’ overhang and loss of the DNA in the next round of replication 
(Lundblad 2012; Mikhelson and Gamaley 2012; Blackburn 1984; Blackburn, Epel, and Lin 
2015; Olovnikov 1973; Watson 1972). In addition to the end replication, environmental 
conditions such as oxidative stress are an additional mechanism of telomere shortening (von 
Zglinicki et al. 1995; von Zglinicki 2000). The progressive loss of mean TL is a hallmark of 195 
replicative senescence of proliferating cells while the amount of telomere shortening can vary 
in different tissues and organs during ageing and disease conditions depending on cell 
proliferation (Benetos et al. 2011) (Benetos et al. 2011)and oxidative stress (von Zglinicki et 
al. 2000).  Human mean TLs are 12-15 kb at birth and shorten down to a minimal TL of 
around 5kb when a DNA damage response and cell cycle arrest are signalled, which can lead 200 
to cellular senescence (Kipling and Cooke 1990; Calado and Dumitriu 2013). Shorter 
telomeres in lymphocytes have been associated with mortality, disease and poor-survival as 
well as reproductive ageing in humans (Cawthon et al. 2003; von Zglinicki et al. 2000; Shay 
2016). Thus, TL in human peripheral blood monocytes (PBMCs) has been proposed as a 
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useful biomarker for human ageing and disease (von Zglinicki et al. 2000; von Zglinicki 205 
2002; Bekaert, De Meyer, and Van Oostveldt 2005).  
Although the mean TL of PMBCs had been employed in age determination in forensic 
medicine, the veracity of this approach is questionable due to the fact that TL is also 
inherited. In addition, more subtle methods for TL measurements considering initial TL as 
well as telomere shortening rates have been proposed (Benetos et al. 2011; Benetos et al. 210 
2013).  TL shortening starts during early gestation in many human tissue types such as heart, 
kidney and brain due to the down-regulation of TA (Ulaner and Giudice 1997; Ulaner et al. 
1998, 2001) and fast postnatal organ specific growth accounts for most of the observed 
differential organ-specific telomere shortening rates (Carneiro et al. 2016).  
Function of telomeres: 215 
The main functions of telomeres are:  
1) Prevention of recognition of linear chromosomal ends as double stranded DNA breaks: 
The shelterin complex and the telomeric loop structure prevent telomeres from being 
identified as a DNA break that would signal a DNA damage response (DDR). TRFs and 
POT1 prevent DDR activation due to the formation of the T-loop (Palm and de Lange 2008); 220 
TRF2 prevents end-to end fusion (Cesare and Karlseder 2012) and POT1 helps to prevent the 
single stranded telomeric 3’ end from being recognised by the DDR complex by forming a 
displacement (D-) loop with the remaining double strand (Yang et al. 2008; Kibe et al. 2010; 
Jacob et al. 2007; Baumann and Price 2010). 
2) Protecting ends of chromosomes from degradation and end-to end fusion: Telomeres 225 
protect chromosomal ends from degradation by nucleases. Different DNA damage 
checkpoint proteins act together with EXO1 and MRE11 nucleases to inhibit proliferation of 
cells undergoing telomere attrition (Xue et al. 2016; Keijzers, Liu, and Rasmussen 2016). 
11 
 
Without the protective capping structure of telomeres, chromosomal ends would fuse together 
and form anaphase bridges during the mitosis leading to a fuse-breakage-fuse cycle. This 230 
process would greatly increase the risk of genomic instability and may result in 
tumourigenesis (Djojosubroto et al. 2003; Meena, Rudolph, and Gunes 2015; Terali and 
Yilmazer 2016; Shay 2016).   
3. Telomeres are sentinels for DNA damage: Telomeres are more susceptible to DNA 
damage than genomic DNA (Petersen, Saretzki, and von Zglinicki 1998) due to their high 235 
guanine content (Henle et al. 1999; Wang et al. 2010) and lack of DNA repair mechanisms 
(Petersen, Saretzki, and von Zglinicki 1998). Telomere-associated DNA damage in the form 
of TIFs (telomere dysfunction-induced foci) or TAFs (telomere associated foci) is hardly ever 
repaired (Takai, Smogorzewska, and de Lange 2003; d'Adda di Fagagna et al. 2003; Takai et 
al. 2011; Hewitt et al. 2012; Fumagalli et al. 2012). This telomere associated damage can 240 
have the same function as critically shortened telomeres in signalling cell cycle arrest.  As the 
“first responders” to hazards of genomic instability, the damaged telomeric DNA initiates a 
sustained DNA damage response, resulting in a cell cycle arrest, and inducing senescence or 
apoptosis thereby protecting the organism from dangerous genetic aberrations and mutations 
(Shay 2016; Blackburn, Epel, and Lin 2015). Telomeres have thus been proposed to be 245 
sentinels for DNA damage (von Zglinicki 2002) and epigenetic sensors of general stress in 
DNA metabolism (Cesare and Karlseder 2012). 
4. Regulation of telomerase access: Shelterin (Fig 1) has a dual role in recruitment of 
telomerase and blocking its access to telomeres (Smogorzewska and de Lange 2004; Palm 
and de Lange 2008; Nandakumar and Cech 2013; Zhang et al. 2013; Schmidt and Cech 250 
2015). POT1 prevents telomerase accessing an intact telomere complex but after hetero-
dimerisation with TPP1, it allows telomerase to become active at telomeres and to extend the 
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3’ overhang in late S-phase (Wang et al. 2007; Zhang et al. 2013; Chu, D'Souza, and 
Autexier 2016).  
5. Regulation of gene transcription/telomere position effect: Telomeres may also regulate 255 
gene transcription via a telomere position effect (TPE) (Robin et al. 2014), whereby genes 
located close to the telomeres are transcribed at a reduced rate. This allows changeable 
epigenetic transcriptional repression permitting genes the ability to switch their transcription 
rate. TPE has been reported to affect the expression of genes involved in stress, growth and 
recognition by the immune system in various invertebrate organisms and in cultured human 260 
cells (Robin et al. 2014). It has recently also been connected to human diseases (Stadler et al. 
2013). Further work examining the role of TPE in gene regulation in human tissues and 
during telomere shortening is needed to unravel its involvement in endometrial diseases.  
6. Non-telomeric functions of telomere associated proteins: Some shelterin proteins also have 
non-telomeric, genomic binding sites that allow extra-telomeric functions such as regulating 265 
transcription of various genes. For example; RAP1 has been shown to regulate female 
obesity, a function unrelated to telomeres (Martinez et al. 2013). Cell type, subcellular 
localisation and development stage specific pathways may regulate the shelterin complex. 
TIN2 has been found in mitochondria (Chen et al. 2012) and a reduction in TIN2 expression 
inhibited glycolysis and reactive oxygen species (ROS) production, enhanced ATP levels and 270 
oxygen consumption in cancer cells. This suggests a link between some shelterin proteins and 
metabolic control, providing an additional mechanism by which telomeric proteins might 
regulate the cellular processes beyond their function at telomeres. Additional non-telomeric 
functions for embryonic development have also been described for TIN2 (Chiang et al. 
2004). 275 
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Telomere maintenance 
Cells can maintain their telomeres via a telomerase dependent pathway or a telomerase 
independent alternative lengthening of telomeres (ALT) pathway (Brien et al. 1997; Bryan et 
al. 1997). Although the latter pathway activation has been limited to particular types of 
cancers (sarcomas) and immortalised cell lines, there are suggestions that the ALT process 280 
may occur under physiological conditions in undifferentiated cells such as stem cells or even 
normal somatic cells (Bojovic et al. 2015; Neumann et al. 2013). There is a general consensus 
that in telomerase competent cells and in most normal cells, the ALT process is redundant 
and hence repressed (Henson et al. 2002). Therefore, in the context of the endometrium, ALT 
is less likely to be relevant and this review focuses mainly on telomerase dependent telomere 285 
maintenance. 
Telomerase: 
Telomerase is a reverse-transcriptase (RNA dependent DNA polymerase) that employs an 
integral RNA subunit harbouring a template sequence to add G-rich telomeric repeats to the 
3’ single-stranded overhang of telomeres (Lingner et al. 1997). The telomerase holoenzyme 290 
has a dimeric structural configuration, where each half contains a human telomerase reverse 
transcriptase (hTERT) and human telomeric RNA component (hTERC) connected by a hinge 
region in the middle (Blackburn 2011; Blackburn and Collins 2011) (Figures 1B & 1C). The 
main components of the telomerase complex are hTERT, hTERC and dyskerin (DKC1) 
(Venteicher et al. 2009) (Figure 1C). In addition, there are various telomerase associated 295 
proteins that interact with these core components (Figure 1). There are 184 telomeres and 
approximately 250 molecules of telomerase and in a cancer cell in late S phase, when 
telomerase is actively recruited to telomere ends (Mozdy and Cech 2006; Xi and Cech 2014; 
Schmidt and Cech 2015). When not active at telomeres, telomerase is localised to Cajal 
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bodies in the nucleus for most of the cell cycle. After the telomerase/telomere interaction, 300 
every single telomerase activation event is thought to add 50–60 nucleotides to most 
telomeres in cancer cells with short TLs in vitro (Zhao et al. 2009; Schmidt and Cech 2015). 
Since the telomere lengthening action is limited to the nucleus, shuttling of the telomerase 
protein hTERT out of the nucleus prevents any telomeric extension.  This shuttling is 
regulated by different domains on the hTERT protein, for example a nuclear localisation 305 
signal (NLS) at amino acid residues 222-240 of hTERT (Chung, Khadka, and Chung 2012), a 
nuclear export signal (Seimiya et al. 2000) as well as a mitochondrial localisation signal 
(Santos et al. 2004) have been described. Furthermore, recent data also suggest that the 
ability of telomerase in extending telomeres may be dependent on pH levels (Ge et al. 2016). 
Acidic pH (6.8) encourages preferential lengthening of short telomeres yet telomerase 310 
lengthens telomeres independent of their lengths at higher pH levels (7.2, 7.4). 
Telomerase components 
Telomerase reverse transcription activity has been demonstrated in an in vitro cell free 
system with just hTERT and hTERC (Weinrich et al. 1997). However, some compounds such 
as dyskerin actively associate with the telomerase complex in a cellular environment and are 315 
important for stability, maturation and function of the enzyme (Cohen et al. 2007). 
hTERT:  
hTERT is the catalytic subunit of telomerase and is often the main rate-limiting factor for 
telomerase enzyme activity (Zhou et al. 2006; Zhang et al. 2013). The hTERT gene is located 
on chromosome 5p15.33 (Shay 2010) and consists of 16 exons and 15 introns spanning ∼35 320 
kb (Cong, Wen, and Bacchetti 1999). There are over 20 spliced variants of hTERT but only 
the wild type (full lengths protein, Figure 1B) exhibits reverse transcriptase activity 
(Hrdlickova, Nehyba, and Bose 2012). The balance between the full lengths hTERT and its 
15 
 
different splice variants has been shown to affect its function (Listerman, Gazzaniga, and 
Blackburn 2014; Radan et al. 2014). In addition to telomere maintenance, hTERT is 325 
implicated in increasing the anti-apoptotic capacity of cells, maintaining pluripotency of stem 
cells and regulating gene expression (for review see (Saretzki 2014)).  
hTERC:  
TERCs are species specific in size and sequence, but highly conserved in their structure and 
all contain a short complementary sequence to the telomeric TTAGGG hexanucleotide repeat 330 
sequence. Human TERC is relatively short (451 nucleotides (nt) compared with >1000nt in 
yeast) ((Theimer and Feigon 2006). The 3’ stabilising element shares an H/ACA motif with 
small nucleolar and small Cajal body RNAs (snoRNA, scaRNA), and in turn associates with 
all four H/ACA RNP components, dyskerin, NOP10, NHP2, and GAR1 (Egan and Collins 
2010) (Figure 1A). hTERC is a non-coding RNA transcribed by RNA polymerase II 335 
(Gallardo and Chartrand 2008; Smekalova et al. 2012). It undergoes subsequent 
exonucleolytic cleavage up to the boundary formed by the H/ACA domain, meaning its co-
transcriptional association with dyskerin is essential for stabilisation, preventing further 
cleavage and nuclear retention (Feng et al. 1995; Fu and Collins 2003; Kiss, Fayet-Lebaron, 
and Jady 2010). This H/ACA domain is mutated in dyskeratosis congenita, where the 340 
disease-associated hTERC variants impair hTERC accumulation. Disease-associated hTERC 
variants with sequence changes outside the H/ACA domain do not affect hTERC RNA 
processing or stability; they instead impose a catalytic defect (Fu and Collins 2003). The 
tetrameric complex of the accessory proteins dyskerin, NOP10, NHP2 and chaperone NAF1 
(which later is replaced by GAR1) bind to hTERC and this association is crucial for normal 345 
telomerase activity.    
16 
 
Dyskerin:  
Dyskerin is an evolutionarily conserved 58kDa, 514-amino-acid large protein (Knight et al. 
1999). In humans, it is encoded by the DKC1 gene located on chromosome Xq28 (Cerrudo et 
al. 2015) and it is generally located in the nucleus. Dyskerin is an essential protein for cellular 350 
survival; thus DKC1 deletion is lethal (Angrisani et al. 2014; Rocchi et al. 2013). In the 
context of telomerase dyskerin plays an established role in the maintenance of telomere 
integrity by stabilising hTERC in the telomerase holoenzyme that is assembled in Cajal 
bodies (Cohen et al. 2007; Gallardo and Chartrand 2008; Gardano et al. 2012). Dyskerin is 
the only component to co-purify with active, endogenous human telomerase (Gardano et al. 355 
2012). Loss of dyskerin binding leads to hTERC degradation and reduction in TA in vivo 
(Shukla et al. 2016). Furthermore, dyskerin has other non-telomerase associated functions 
essential to elementary cellular events such as mRNA translation, growth and proliferation. 
Dyskerin may regulate these functions via directing the isomerisation of specific uridines to 
pseudouridines by acting as a catalytic pseudouridine synthase and by acting through the 360 
snoRNA-derived miRNA regulatory pathway, thus affecting different biological processes 
(reviewed in (Angrisani et al. 2014)).  
Other accessory proteins of telomerase 
Apart from NOP10, NHP2, and GAR1 which form the H/ACA motif-associated tetramer 
with dyskerin (Fig 1), there are a plethora of other proteins (some are listed in Table 1) 365 
associated with telomerase with roles including: assembly, processing of telomerase, 
localisation and accessibility to telomeres. In addition to these proteins telomerase interacts 
with many others which are required for the formation of the appropriate structure and its 
stabilization, however their importance in TA is unknown (Smekalova et al. 2012). It is 
important also to appreciate the close relationship of telomerase with many cell cycle 370 
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regulating, tumour suppressor, pluripotency and EMT (epithelial to mesenchymal transition) 
related proteins and pathways, such as Wnt/β-catenin, Cyclin D1, BCL-2, OCT-4, p53, 
EGFR etc (Ding et al. 2011; Tang et al. 2016; Listerman, Gazzaniga, and Blackburn 2014; 
Xue et al. 2016). Interestingly, recent data has suggested that the DNA damage response 
kinases ATM and ATR are required to recruit telomerase to telomeres via a TRF1 regulated 375 
pathway (Tong et al. 2015), while Carol Greider’s group has further highlighted a central role 
of the ATM pathway in regulating telomere addition (Lee, Bohrson, et al. 2015). In yeast, 
there exists a counting mechanism involving the shelterin RAP1, which prevents ATM 
accessing/activating telomerase on long telomeres thereby regulating TL(Yuan et al. 2013). 
However, whether a similar feedback mechanism exists in human cells is not yet 380 
known(Runge and Lustig 2016). These findings are only beginning to unravel the intricate 
cellular pathways that are converging to regulate telomerase and telomere biology.   
Functions of telomerase 
1) Telomere maintenance: In eukaryotic cells, TA counteracts the end-replication problem 
and elongates the 3’ single strand in the absence of a DNA template. The subsequent 385 
replication of the complementary strand then will be possible by the conventional DNA 
replication in the next S-phase. The human telomerase complex consisting of hTERC and 
hTERT is targeted to telomeres specifically in the late S phase of the cell cycle (Hug and 
Lingner 2006). Recent work has suggested that hTERT remains bound to hTERC for most of 
the cell cycle (Vogan and Collins 2015). The telomerase holoenzyme Cajal body-associated 390 
protein, TCAB1, is released from hTERC during cell cycle progression in mitotic cells 
coincident with TCAB1 delocalization from Cajal bodies (Vogan and Collins 2015). This 
observation proposes that TCAB1 and hTERC association may license the catalytically active 
hTERT-hTERC holoenzyme for recruitment to telomeres in the G1 phase of the cell cycle. 
TRF1 is the shelterin protein that is primarily responsible for regulation of an efficient 395 
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replication of telomeric DNA (Sfeir et al. 2009). Apparently not all telomeres are required to 
be elongated by telomerase in each DNA replication round but there might be preferential 
lengthening of the shortest telomeres in telomerase active cells to ensure all the TLs remain 
above a critical length that would otherwise initiate activation of apoptotic and cell cycle 
arresting pathways (Fakhoury et al. 2010; D'Souza et al. 2013). The exact mechanism of how 400 
telomerase extends telomeres with various lengths differentially is still not well understood. 
2) Non-telomeric functions of the telomerase component hTERT. Although telomere 
protection/lengthening is the most widely studied function of telomerase, there has been a 
considerable amount of evidence on non-telomeric functions of the protein subunit hTERT 
such as promoting cellular proliferation/growth, survival, retaining an undifferentiated status, 405 
as well as increasing of motility and metabolism (reviewed in (Saretzki 2014) and (Terali and 
Yilmazer 2016)). Recent evidence also suggests that hTERT stimulates ribosomal DNA 
transcription, particularly under hyper-proliferative conditions (Gonzalez et al. 2014). 
Protection of mitochondrial function under oxidative stress has been proposed as an 
important role of hTERT in various cell types, it was associated with reduction in oxidative 410 
stress and sensitivity to apoptosis as well as a reduction in DNA damage (Ahmed et al. 2008; 
Singhapol et al. 2013). While initial studies on the beneficial role of mitochondrial hTERT 
were conducted mainly in vitro in cell culture, recent data describe a beneficial effect also in 
vivo, for example in vascular function (Beyer et al. 2016). Telomerase may interact with 
various well established proliferative pathways including EGFR signalling (Smith, Coller, 415 
and Roberts 2003), MYC and Wnt/β-catenin pathways (Park et al. 2009; Hoffmeyer et al. 
2012)./ Telomerase has been shown to promote cell survival by blocking the death receptor 
(Dudognon et al. 2004) as well as down regulating pro-apoptotic genes such as BAX and 
BCL-2 (Del Bufalo et al. 2005; Massard et al. 2006) in addition to suppressing mitochondrial 
and endoplasmic reticulum stress induced cell death (Zhou et al. 2006). Telomerase inhibition 420 
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in stem cells has induced differentiation and loss of pluripotency genes, suggesting a role as a 
pluripotency gene in embryonic stem cells maintaining an undifferentiated status (Saretzki et 
al. 2008; Yang et al. 2008; Liu et al. 2013).  
The endometrium  
Human endometrium lines the uterine cavity and is organised into two functionally distinct 425 
layers: the superficial functionalis and deeper basalis (Valentijn et al. 2013); (Hapangama, 
Kamal, and Bulmer 2015). The transient, exquisitely hormone responsive functionalis exists 
only during the reproductive life of a woman, whereas the permanent, relatively hormonally 
unresponsive basalis layer persists throughout her whole life. The endometrial menstrual 
cycle is an exclusive phenomenon to upper order primates and is regulated by ovarian steroid 430 
hormonal signals (Hapangama, Kamal, and Bulmer 2015; Kamal, Tempest, et al. 2016; 
Kamal, Bulmer, et al. 2016) (Figure 2A).  
Endometrium is the primary target organ for ovarian steroid hormones and the endometrial 
cell cycle is intricately regulated by them. The reproductive life span of a woman is dictated 
by ovarian function. It commences with the menarche and finishes with the menopause. 435 
During that period, an average woman endures about 400 menstrual cycles in which the 
functionalis layer of the endometrium undergoes a well-defined cycle of proliferation, 
differentiation, menstrual shedding followed by regeneration. Ovarian steroid hormones 
regulate this endometrial cycle via their cognate receptors (reviewed in (Hapangama, Kamal, 
and Bulmer 2015; Kamal, Tempest, et al. 2016)). It is generally accepted that estrogen is the 440 
trophic hormone of the endometrium, where it induces cellular growth and proliferation; 
whilst progesterone influences cellular differentiation, and counteracts proliferation and other 
estrogenic effects (Hapangama 2003). The third ovarian steroid hormone, androgen, is also 
postulated to impact on the endometrial cycle, yet unlike the aforementioned hormones, the 
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exact details of androgenic regulation of the endometrium are yet to be fully elucidated. The 445 
huge regenerative potential seen with the monthly endometrial cycle is unparalleled by other 
tissues; and the exact reason for this menstrual shedding, which is biologically a very 
expensive process, is yet unknown.  
Telomerase and Telomeres in endometrial tissue: functional relevance 
TA is high in the premenopausal endometrial functionalis (Kyo et al. 1997) (Figure 2C-D). 450 
Its dynamic changes regulated by the ovarian cycle are well established and correlate with 
glandular proliferation (Williams et al. 2001; Hapangama, Turner, Drury, Quenby, et al. 
2008; Hapangama et al. 2009). Our recent work further demonstrates similar dynamic 
changes in the mean endometrial TLs across the menstrual cycle (Valentijn et al. 2015) 
(Figure 2B). Once the ovarian hormone production has ceased, the relatively quiescent 455 
postmenopausal endometrium expresses low levels of TA (Brien et al. 1997) (Tanaka et al. 
1998).  
When examining distinct cellular compartments within the endometrium, stromal cells 
regardless of the cycle phase maintained longer TLs compared with the epithelial cells. 
However they demonstrated absent or significantly lower TA (Figure 3A-C) and hTERC 460 
expression compared with the epithelial cells (Yokoyama et al. 1998; Tanaka et al. 1998; 
Valentijn et al. 2015), (Vidal et al. 2002). Data from a previous study which employed in situ 
assessment of endometrial TLs also demonstrates that glandular epithelium of the 
endometrial functionalis to possess the shortest TL (Cervello et al. 2012) (Figure 3D). 
Furthermore, the proliferating endometrial epithelial cells have the highest TA that correlates 465 
negatively with TL (Valentijn et al. 2015) (Figure 3B). This suggests that in the epithelial 
cells the high TA preferentially preserves the short telomeres in order to avoid a critically 
short length. In rodents, estrogen increases the pH in the uterine fluid, while progesterone has 
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the opposite effect (Chinigarzadeh, Muniandy, and Salleh 2016). It can therefore be 
speculated that low pH in the proliferative phase may preferentially direct telomerase 470 
function to the short telomeres in endometrial epithelial cells. This is in accordance with the 
recent evidence regarding pH dependent telomerase function (Ge et al. 2016). Further studies 
would be required to fully investigate and confirm this possibility.    
Moreover, endometrial hTERT may have extra-telomeric functions. Direct in vitro inhibition 
of TA with the TERC inhibitor ‘imetelstat’ inhibited endometrial cell proliferation and 475 
disrupted gland formation by healthy epithelial cells (Valentijn et al. 2015). In contrast, 
overexpressing hTERT in endometrial stromal cells did not increase cell proliferation rate or 
hormone responsiveness (Barbier et al. 2005) similar to the other non-endometrial fibroblasts 
(Ahmed et al. 2008). Thus, there might be a specific co-regulation of TA and proliferative 
capacity limited to the endometrial epithelial cells or epithelial cells in general.. Other groups 480 
have found a correlation between TA in ovarian granulosa cells and their proliferation and 
differentiation status which is also under the control of growth factors and steroid hormones, 
similar to endometrial epithelium (Chronowska 2012). Importantly, although it has been 
possible to immortalise benign endometrial stromal cells by over-expressing hTERT (Krikun, 
Mor, and Lockwood 2006), immortalisation of endometrial epithelial cells using a similar 485 
process has not been equally successful. This might be due to the fact that epithelial cells are 
likely to require an additional inhibition of the p16INK4a tumour suppressor in order to be 
immortalised by hTERT overexpression (Kiyono et al. 1998; Farwell et al. 2000; Novak et al. 
2009; Shao et al. 2008).  
Previously reported immortalisation of benign human endometrial epithelial cells with 490 
hTERT overexpression (Kyo et al. 2003), has not been successfully replicated.  This is an 
important fact, as the only other immortalised benign endometrial epithelial cell line that was 
subsequently generated by telomerase over-expression (Hombach-Klonisch et al. 2005) was 
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later confirmed to be the misidentified breast cell line MCF-7(Korch et al. 2012). This 
particular cell line was widely available to several groups leading to many publications e.g. 495 
(King et al. 2010). Unfortunately, the reportedly immortalised epithelial cell line generated 
by Kyo and colleagues (Kyo et al. 2003) has not undergone similar scrutiny and has not been 
available to other groups for further confirmatory studies for authenticity. In summary, we 
conclude that there are fundamental differences in telomerase function between endometrial 
epithelial and stromal cells. Mere presence of telomerase may result in a survival advantage 500 
for stroma, while epithelial cell proliferation may be regulated by telomerase. Additional 
factors than TA seem to be necessary for the long term survival and immortalisation of 
epithelial cells in culture.  
We are just beginning to understand the importance of extra-telomeric functions of telomere 
and telomerase components; for example, RAP1 has an extra-telomeric function on stromal 505 
cell decidualisation in the rat endometrium (Kusama et al. 2014). Further examination of 
extra-telomeric functions of telomerase/telomeric proteins in the endometrium is warranted to 
further reveal their interplay with other cell cycle regulators specific to the endometrium.  
Hormonal regulation of telomerase in epithelial cells 
TA can be regulated at multiple levels e.g. transcription, splicing, epigenetic and post-510 
translational modification (reviewed in (Fojtova and Fajkus 2014); (Lewis and Tollefsbol 
2016) (Akincilar, Unal, and Tergaonkar 2016)). Most human somatic tissue has absent or low 
levels of TA which is tightly regulated compared with the high and easily detectable levels 
seen in cancer cells and in germ line/stem cells. Thus, the initial studies on telomerase 
regulation were conducted in the context of developmental/ stem cell biology or in cancer 515 
cells (reviewed in (Batista 2014); (Huang et al. 2014), (Gladych, Wojtyla, and Rubis 2011)). 
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However, in this review, we focus primarily on the hormonal regulation of telomerase at a 
normal, physiological level in the endometrium which is pivotal to its function.   
Estrogen  
Early work on the hormone responsive breast cancer cell line MCF-7 showed that estrogen 520 
up-regulates TA and hTERT gene expression via direct and indirect effects on the hTERT 
promoter (Kyo et al. 1999). Gel shift assays on MCF-7 cells further revealed that there is an 
imperfect palindromic estrogen-responsive element (ERE) in the hTERT promoter that 
specifically binds to estrogen receptor (ER) and is responsible for transcriptional activation 
by ligand-activated ER (Kyo et al. 1999). Further confirmation of 17β-estradiol (E2) induced 525 
transcription of hTERT via ERα was also reported in various other cell types, including 
ovarian epithelial cells (Kimura et al. 2004; Gladych, Wojtyla, and Rubis 2011); ovarian 
stromal cells (Misiti et al. 2000), mesenchymal stem cells (Cha et al. 2008), and human 
umbilical vein endothelial cells (HUVECs) (Hiyama and Hiyama 2007). Although ChIP 
assays in prostate cells suggested a recruitment of both ER subtypes to the hTERT promotor, 530 
its induction by ERβ in other cells remains controversial (Nanni et al. 2002). 
There is some evidence that longer exposure to endogenous estrogen (length of reproductive 
years of life) might correlate with greater TLs and TA in PBMCs (Pines 2013). In other 
words, longer TLs seem to be present in different tissues and be associated with longer 
reproductive life. E2 increased TA and TERT mRNA in heart, liver and brain tissue in an 535 
ovariectomised rat model (Cen et al. 2015). However, mature peripheral T cells do not 
respond to E2 with changes in expression or function of telomerase (Benko, Olsen, and 
Kovacs 2012) suggesting that the effect of estrogen on telomerase is tissue/cell specific. 
Finally, the relative longevity of women compared with men has been speculated to be 
related to the effects of estrogen induced telomerase on telomere protection (Leri et al. 2000; 540 
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Gopalakrishnan et al. 2013; Barrett and Richardson 2011; Calado et al. 2009; Cen et al. 
2015). More active telomerase was found in cardiac myocytes from female rats which seems 
to correspond to higher myocyte numbers in older women compared to myocyte loss in older 
men (Leri et al. 2000). Others have suggested that reduction of oxidative stress by estrogens 
may result in longer telomeres in tissues such as brain and liver (Vina et al. 2005).  Greater 545 
female longevity is suggested to possibly be connected to the female exposure to estrogens 
(Muezzinler, Zaineddin, and Brenner 2013). However, a recent longitudinal study reports a 
higher rate of PBMC TL attrition in the premenopausal period than in the postmenopausal 
period (Dalgard et al. 2015) with the authors proposing the opposite effect of estrogen on 
leucocyte turnover and menstrual bleeding. Thus, the influence of estrogen on TL and female 550 
longevity is still controversial.  
There is in vivo and in vitro evidence suggesting that estrogens are able to induce TA and 
hTERT expression in the endometrium (Tanaka et al. 1998; Kyo et al. 1999; Vidal et al. 
2002). In contrast, postmenopausal endometrium and endometrium treated with anti-estrogen 
drugs exhibited decreased TA (Tanaka et al. 1998). Furthermore, long term treatment with 555 
clinically relevant doses of conjugated E2 increased TERC expression preferentially in 
endometrial glands of ovariectomized female cynomolgus macaques (Macaca fascicularis) 
(Vidal et al. 2002). Increased TERC levels also correlate with higher proliferation and 
progesterone receptor expression in the endometrium of treated animals (Vidal et al. 2002). 
Both these parameters are known to be regulated by estrogen in the endometrium 560 
(Hapangama, Kamal, and Bulmer 2015). In the ER positive, hormone responsive endometrial 
epithelial adenocarcinoma cell line (Ishikawa cells) E2 induced TA and hTERT mRNA levels 
via a MAPK dependent pathway in an ERα dependent fashion (Zhou et al. 2006). In contrast, 
isolated primary epithelial cells (Tanaka et al. 1998) or intact endometrium in short-term 
explant culture did not show a significant response to E2 on TA (Valentijn et al. 2015). 565 
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Conversely, co-cultured primary endometrial epithelial and stromal cells responded to E2 or a 
mitogenic FGF stimulus, suggesting that the E2 effect on telomerase induction may be 
enhanced or mediated by stroma and/or the duration of E2 treatment (Oshita et al. 2004).   
Progesterone  
Although progesterone has diverse effects on hTERT mRNA expression in progesterone 570 
receptor (PR) expressing breast and endometrial cancer cell lines, the mechanisms by which 
hTERT expression is regulated by progesterone appear to be complex. The hTERT promoter 
lacks a canonical progesterone-responsive element (Wang et al. 2000), therefore classical PR 
mediated direct effects are less likely. The role of recently described progesterone receptor 
membrane components (PGRMC) 1 and 2 on telomerase regulation has not yet been 575 
demonstrated (Bunch et al. 2014). In a breast cancer cell line synthetic progestogen, 
medroxyprogesterone acetate (MPA), inhibited hTERT mRNA transcription even in the 
presence of estrogen (Wang et al. 2000; Lebeau et al. 2002) and arrested cells in late G1phase 
(Lebeau et al. 2002) with the induction of p21 (Lange, Richer, and Horwitz 1999; Wang et al. 
2000). There is evidence for cell cycle-dependent regulation of telomere synthesis and 580 
telomerase gene expression in healthy hormone responsive human cells by progesterone 
(Wang et al. 2000; Tomlinson et al. 2006).  
Since endometrial TA, hTERT mRNA/protein and hTERC levels reach their nadir during the 
progesterone dominant mid-secretory phase; progesterone is thought to negatively regulate 
endometrial telomerase (Williams et al. 2001; Hapangama, Turner, Drury, Quenby, et al. 585 
2008; Hapangama et al. 2009; Valentijn et al. 2015). The shortest endometrial TL were also 
measured in the mid-secretory phase indicating a telomere lengthening/maintenance function 
for endometrial TA (Valentijn et al. 2015). Exogenous progestogen administration is known 
to inhibit endometrial epithelial proliferation (Kurita et al. 1998; Shimizu et al. 2010) and we 
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have recently shown this progestogen-induced decreased endometrial cell proliferation to be 590 
associated with a significant decrease in TA (Valentijn et al. 2015). Interestingly, the 
inhibition of TA in the progesterone-dominant secretory phase is associated with an induction 
of endometrial p21 and corresponds to a non-DNA damage induced cell cycle arrest function 
of p21 (Toki et al. 1998) (Yoshimura et al. 2007). We can speculate that progesterone 
induced telomerase suppression might result in short endometrial epithelial telomeres 595 
(Hapangama et al. 2009) (Valentijn et al. 2015) and perhaps influence changes in endometrial 
epithelial cell cycle via p21 induction (Aix et al. 2016). Taken together, the hTERT gene may 
be a target of progesterone and the well-established progesterone induced down-regulation of 
the endometrial cell cycle may involve telomerase.   
Androgens 600 
Androgens such as dihydrotestosterone (DHT) induced TA at the G1 phase of the cell cycle 
in the androgen sensitive prostate cancer cell line LnCAP (Thelen et al. 2004). However, 
there was no modulation of TA by androgens in either androgen insensitive prostate cancer 
cell lines (TSU-Pr1, DU145), or in normal human prostate cells (Soda et al. 2000). In a recent 
study in men, serum DHT and E2 levels were shown to correlate with TL in PMBC, 605 
suggesting that both hormones may have a synergistic influence on TA (Yeap et al. 2016). 
However, caution should be taken when interpreting this observation as the authors have not 
demonstrated a direct regulatory effect. Oral treatment with Danazol (a synthetic steroid with 
weak androgenic properties) for 2 years resulted in universal leucocyte telomere elongation in 
both male and female patients with diseases such as bone marrow failure, liver cirrhosis and 610 
pulmonary fibrosis known to involve telomeres (Townsley et al. 2016). The intra-cellular 
metabolism of testosterone to estrogens is well described (Sasano et al. 2008). Androgens 
appear to regulate telomerase expression and activity mainly by aromatisation of testosterone 
to estrogens through ERα in normal peripheral blood lymphocytes and human bone marrow-
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derived CD34(+) cells in vitro (Calado et al. 2009). Therefore, it is difficult to clearly 615 
ascertain if the observed effects of androgenic compounds were related to the direct effects 
on the androgens receptor (AR) or indirectly mediated via ER.  
Endometrium expresses AR yet the direct specific effects of androgens in normal 
endometrium are only beginning to be understood. There is no published work yet examining 
the effects of androgens in endometrial telomerase regulation. 620 
Other hormones relevant for the endometrium 
Melatonin appears to regulate hTERT and hTERC expression in MCF-7 cells (Leon-Blanco 
et al. 2004) while dexamethasone reduced TA through the inhibition of TERT expression 
before induction of apoptosis (Akiyama et al. 2002). In contrast, hydrocortisone did not affect 
TA in human leucocytes (Calado et al. 2009). Therefore, the evidence for other non-ovarian 625 
steroidal hormones having a potential regulatory function of endometrial telomerase is 
limited and they will not be further discussed in this review.   
Endometrial stem cells and telomerase 
The involvement of stem/progenitor cells (SPCs) in the endometrial regenerative process has 
been suggested for a long time (Prianishnikov 1978). After menstrual shedding, a new 630 
functionalis layer is thought to  regenerate from the remaining SPC rich basalis (Valentijn et 
al. 2013; Hapangama, Kamal, and Bulmer 2015) and SPCs in many other tissues have the 
potential to activate telomerase (Hiyama and Hiyama 2007). Interestingly, the available 
evidence for the differences in TA between the endometrial basalis and the functionalis is 
controversial. A study in which different endometrial layers were crudely isolated by 635 
scraping (using a curette or a scalpel) suggested that TA is lower in the basalis (Bonatz et al. 
1998); whereas isolated basalis epithelial cells, identified by expression of the surface marker 
SSEA1 from primary endometrial epithelial cells in short term culture showed higher TA 
28 
 
than  functionalis epithelial cells (Valentijn et al. 2013). Our study examined only sorted 
endometrial epithelial cells and telomerase expression and TA are limited mainly to the 640 
epithelial cells (Tanaka et al. 1998; Yokoyama et al. 1998; Valentijn et al. 2015).  Therefore 
both studies should have demonstrated similar results. The reasons for this contradictory 
observation could be due to the fact that epithelial SPC cells are likely to be activated during 
isolation and cultivation in the latter study, which removed the epithelial SPC cells from its 
niche, a process known to induce telomerase (Engelhardt et al. 1997). Furthermore, the 645 
presumed basalis tissue obtained by scraping the myometrium in the former study might have 
contained a higher proportion of myometrial tissue with low TA levels.  
The available evidence suggests that the endometrium contains multiple progenitor cell 
populations. Cells with some stem cell properties have been isolated from the human 
endometrium expressing phenotypical markers of epithelial, stromal, leucocyte and vascular 650 
origin (Chan, Schwab, and Gargett 2004; Masuda et al. 2010; Cervello et al. 2011). Freshly 
isolated undifferentiated side population cells containing all these primitive cell types from 
human endometrium also expressed TA (Cervello et al. 2011). Presence of TA in the most 
widely characterised and studied endometrial SPC cell subtype; the endometrial stromal 
(mesenchymal) SPCs (Gargett, Schwab, and Deane 2016), is yet to be fully described. 655 
Human mesenchymal stem cells (hMSC) from other locations are known to have negative or 
very low TA (Zimmermann et al. 2003; Tichon et al. 2009; Ogura et al. 2014). However, 
there is a report suggesting that early passages of endometrial stromal SPCs isolated on the 
basis of their expression of the putative mesenchymal stem cell marker CD146 express 
hTERT protein and mRNA but the authors did not measure TA (Yang X 2011). Furthermore, 660 
isolated primary endometrial stromal cells had low but measurable TA in our recent study 
(Valentijn et al. 2015). Our unpublished data also suggest that TA in isolated primary stromal 
cells positively correlated with mean TLs, suggesting that telomerase expression may have a 
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telomere lengthening function in these cells (Figure 3). It will be interesting in the future to 
confirm these preliminary findings and examine the functional relevance of TA to TL in the 665 
different endometrial SPC subtypes. However, the low amount of TA in stromal cells and 
problems with the specificity of the currently available anti-hTERT antibodies that are 
suitable for IHC/IF make this task  difficult. Interestingly, in a recent study, there were rare 
telomerase expressing cells in murine endometrial stroma that may represent SPC cells 
(Deane et al. 2016). However, due to the fact that telomerase is expressed constitutively in 670 
many mouse tissues unlike in humans , it is difficult to evaluate the significance/relevance of 
this finding in the context of the human endometrium.  
The only characterised human endometrial epithelial cell subpopulation (cells that express 
surface marker SSEA-1, nuclear SOX9 and nuclear β-catenin) that exhibits progenitor 
properties in vitro, also showed high TA and longer TL compared with their more 675 
differentiated epithelial cell counterparts (Gargett, Schwab, and Deane 2016; Valentijn et al. 
2013). Importantly, these cells with high TA were able to produce endometrial gland like 
structures in 3D in vitro culture and when confronted with a 2D environment they were able 
to produce a monolayer, functionally akin to the re-epithelialisation of the denuded 
endometrial surface after shedding of the functionalis (Valentijn et al. 2015). Finally, in a 680 
study employing immunofluorescence microscopy, the potential stem cell marker Mushashi 1 
also co-localised with the telomerase protein hTERT in the endometrial epithelium (Gotte et 
al. 2008). However, Mushashi1 expressing cells have not been shown yet to have stem cell 
characteristics in functional studies. 
Taken together, the above data suggests that endometrial SPC cells (basalis SSEA1+ 685 
epithelial cells and possibly stromal SPCs) have TA (Valentijn et al. 2015). The exact 
function of telomerase in the epithelial and in stromal SPCs is not fully understood yet. 
Similar to the intestine, epidermis and other epithelial tissues and organs, endometrium may 
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also have multiple, heterogeneous epithelial stem cell populations with or without a 
functional hierarchy (Goodell, Nguyen, and Shroyer 2015; Pirvulet 2015; Schepers et al. 690 
2011) and they may have corresponding differential telomerase activation states. Active, 
more differentiated progenitor cells involved in normal physiological regeneration might 
have higher TA; while the true, dormant/quiescent stem cell population do not express any or 
very low levels of TA until they are activated. The quiescent stem cell population may have 
low TA during normal physiological regeneration of endometrium and only show high TA if 695 
challenged by extensive tissue disruption or when progenitors are compromised, such as after 
iatrogenic endometrial ablation (Hiyama and Hiyama 2007; Biswas et al. 2015). Further 
studies on telomere biology and telomerase function in the endometrial stem cell population 
are required in order to elucidate altered pathways relevant to endometrial proliferative 
diseases. Since stem cells are hypothesised to harbour defects specific to chronic endometrial 700 
pathologies (Gargett et al. 2014; Sourial, Tempest, and Hapangama 2014; Figueira et al. 
2011), treatment strategies directed towards them may prove to be curative.  
Role of telomerase in the pathological conditions of the endometrium: 
Endometriosis 
Endometriosis is a common chronic inflammatory disease, defined by the existence of 705 
endometrial like stroma and epithelial tissue in ectopic sites, outside the uterine cavity. Since 
endometrial tissue is intensely responsive to ovarian hormones, the main stimulus for the 
growth of ectopic endometriotic lesions is estrogen (Hapangama, Kamal, and Bulmer 2015; 
Hapangama and Bulmer 2016; Kamal, Tempest, et al. 2016; Sourial, Tempest, and 
Hapangama 2014) and progesterone resistance has been proposed as a fundamental feature of 710 
ectopic endometriotic lesions (Bulun et al. 2006). The endometrium of women with 
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endometriosis has been shown to be different to that of healthy fertile women (Hapangama et 
al. 2012; Mathew et al. 2016).  
There is a large body of evidence demonstrating that high TA, expression of hTERT and 
protein levels associated with longer mean endometrial TLs are features of the eutopic 715 
secretory endometrium of women with endometriosis (Hapangama et al. 2010; Hapangama et 
al. 2009; Hapangama, Turner, Drury, Quenby, et al. 2008; Kim et al. 2007; Valentijn et al. 
2013; Valentijn et al. 2015; Mafra et al. 2014). These changes have been proposed to 
contribute to the functional endometrial abnormalities that result in clinical manifestation of 
subfertility as well as propagating ectopic lesions. Considering the known pro-survival 720 
function of telomerase, the high TA in late-secretory endometrium of women with 
endometriosis (Hapangama, Turner, Drury, Quenby, et al. 2008) might be responsible for the 
survival of cells that are shed into the peritoneal cavity during retrograde menstruation 
(Hapangama et al. 2010). The preferential survival of these cells and their enhanced 
replicative capacity due to high TA could facilitate implantation/establishment of ectopic 725 
lesions (Hapangama et al. 2010; Valentijn et al. 2015) (Figure 4). This corresponds well with 
the finding of high TA and hTERT mRNA/protein levels in active peritoneal ectopic 
endometriotic lesions. In addition, ectopic epithelial cells display also longer relative TL 
compared with eutopic epithelial cells from the same patient (Valentijn et al. 2015; 
Hapangama, Turner, Drury, Quenby, et al. 2008). This observation seems to be in agreement 730 
with the progesterone resistance described in the pathogenesis of endometriosis (Bulun et al. 
2006; Sourial, Tempest, and Hapangama 2014), where the development of ectopic 
endometriotic lesions may increase TA due to the failure of endogenous progesterone to 
inhibit telomerase at the ectopic site. We have already shown that dysregulation of telomerase 
is an important early change in endometriotic cells since high TA was required for the early 735 
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establishment of ectopic lesions in a baboon model of induced endometriosis (Hapangama et 
al. 2010) (Figure 4).(Afshar et al. 2013)   
Furthermore, in the baboon model establishment of ectopic lesions was associated with 
induction of high TA and TERT expression in the eutopic endometrium (Hapangama et al 
2010). Interestingly, the initial induction of endometriosis was associated with activation of 740 
EGF signalling in the eutopic endometrium of the baboon model (Afshar et al. 2013) and 
EGF signalling was associated with up-regulation of TA in normal ovarian surface epithelial 
cells (Bermudez et al. 2008). A similar scenario might be happening in the eutopic 
endometrium in the baboon model. Eutopic endometrial cells with high TA can subsequently 
initiate more ectopic lesions after retrograde menstruation contributing to a self-propagation 745 
cycle of the disease (Hapangama et al. 2010) (Figure 4). Ovarian endometriotic epithelial 
cells were successfully immortalised by combinatorial transfection of human cyclinD1, cdk4 
and hTERT genes, whereas the introduction of hTERT alone, or together with cdk4, was 
insufficient for immortalisation of these cells (Bono et al. 2012). Therefore, telomerase alone 
may not be sufficient for the apparent survival advantage displayed by the endometriotic cells 750 
(Fig 4). 
SPCs are suggested to play a key role in the pathogenesis of endometriosis (Figueira et al. 
2011; Gargett et al. 2014; Sourial, Tempest, and Hapangama 2014). Intriguingly, the 
epithelial cells of ectopic lesions show phenotypic similarities with SSEA1 expressing basalis 
epithelial cells (Valentijn et al. 2013; Valentijn et al. 2015). Recent data also suggests that the 755 
tumour suppressor protein ARID1A might negatively regulate hTERT transcription and TA. 
Induction of ARID1A repressed transcription of hTERT via binding to a regulatory element 
on the hTERT promoter, and promoted a repressive histone mode via occupying SIN3A and 
H3K9me3 (Rahmanto et al. 2016). ARID1A is a member of the SWI/SNF chromatin 
remodelling complex, and is reported to be frequently mutated in two epithelial ovarian 760 
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carcinoma subtypes: ovarian clear cell carcinomas and endometrioid ovarian carcinomas 
(Samartzis et al. 2013; Grandi et al. 2015). These cancers have been molecularly and 
epidemiologically linked to endometriosis with approximately 20% of benign ovarian 
endometriosis lesions having a loss of BAF250a (encoded by ARID1A) expression (Xiao, 
Awadallah, and Xin 2012). Therefore, it is conceivable that hTERT expression may be 765 
potentially involved in carcinogenesis associated with the loss of ARID1A. However, the 
seemingly vigorous endometrial regulation of telomerase via ovarian hormones and the fact 
that TA levels are high and constitutively expressed in proliferating endometrial epithelial 
cells may be responsible for the apparently rare incidence of such transformation (Zafrakas et 
al. 2014; Ness et al. 2015). TL in peripheral lymphocytes of women with endometriosis 770 
compared to healthy controls did not differ in our studies (Hapangama, Turner, Drury, 
Quenby, et al. 2008; Hapangama et al. 2009) while others have reported longer telomeres in 
PBMCs from women with endometriosis (Dracxler et al. 2014). The reason for this observed 
difference could be attributed to the influence of different demographic features known to 
affect PMBC TL such as age, BMI and ethnicity. These factors were not accounted for and 775 
significantly differ between the 2 patient groups in the latter study and may account for the 
different TLs observed rather than endometriosis. Our studies controlled for these 
demographical parameters as well as the menstrual cycle phase and did not show an 
endometriosis associated significant difference in PMBC TLs (Hapangama et al. 2009; 
Hapangama, Turner, Drury, Quenby, et al. 2008).  780 
Endometriosis shares some of the typical features of increased synthesis of pro-inflammatory 
cytokines and the imbalance between pro-inflammatory and anti-inflammatory cytokines 
with other chronic inflammatory diseases (Figure 4, Souriel et al 2014). Interestingly, 
telomere attrition and decreased TA have been associated with many chronic inflammatory 
diseases (Zhang et al. 2016).  Although opposite changes in endometrial telomere regulation 785 
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and involvement of high TA in endometriosis have been confirmed by various studies to date 
(Hapangama et al. 2009; Hapangama, Turner, Drury, Quenby, et al. 2008; Hapangama et al. 
2010; Kim et al. 2007; Valentijn et al. 2013; Valentijn et al. 2015; Mafra et al. 2014), this 
knowledge is yet to be translated into a therapeutic solution. Since endometriosis is 
postulated to be a progesterone resistant condition (Bulun et al. 2006) and since telomerase 790 
inhibition is a downstream effector of progesterone (Valentijn et al. 2015) the option of  
telomerase inhibition must be further explored as an attractive, non-hormonal treatment for 
endometriosis.  
Endometrial polyps 
Endometrial polyps are defined as abnormal outgrowth of hypertrophic endometrial tissue 795 
consisting of a monoclonal overgrowth of endometrial stromal cells with inclusion of a non-
neoplastic glandular component (Hapangama and Bulmer 2016). Endometrial stimulation by 
estrogen is postulated as the main driving force for endometrial polyp formation and this is 
supported by the observation that the use of tamoxifen, which acts as an ER agonist on the 
endometrium, increases the risk of developing endometrial polyps. Lower levels of hTERT 800 
protein in endometrial polyps have been reported compared with normal endometrium in the 
proliferative phase (Hu and Yuan 2011). CD146 expressing mesenchymal SPCs derived from 
endometrial polyps did not express any hTERT (Ding et al. 2011). Jointly these studies 
suggest that benign endometrial polyps with increased stromal growth have low telomerase 
and TA is less likely to play an essential role in them. However, telomerase biology in polyps 805 
with epithelial hyperplasia/atypia remains to be explored in future studies.     
Reproductive failure 
Embryo implantation occurs during the window of implantation in the mid-secretory phase. 
The mid-secretory phase is defined by the dominant action of progesterone with maximum 
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cell differentiation in an environment where endometrial glandular proliferation indices are at 810 
their nadir. This period is also associated with the lowest endometrial TA and the shortest 
mean TL (Williams et al. 2001; Valentijn et al. 2015) suggesting a requirement in low 
endometrial TA for the establishment of an early pregnancy. This suppression of TA in the 
endometrium of fertile women has been proposed as a necessary process in order to allow 
endometrial cells to undergo differentiation with cellular apoptosis/senescence required to 815 
make space for the invading embryo (Williams et al. 2001; Hapangama et al. 2009; 
Hapangama, Turner, Drury, Quenby, et al. 2008; Hapangama et al. 2010). It is therefore not 
surprising that significantly high telomerase expression and TA was observed in endometrial 
tissue of women with recurrent reproductive failure (Hapangama, Turner, Drury, Martin-
Ruiz, et al. 2008; Long et al. 2016). The mid-secretory endometria of women with recurrent 820 
miscarriages, recurrent embryo loss and recurrent implantation failure all showed high 
endometrial TA (Hapangama, Turner, Drury, Martin-Ruiz, et al. 2008; Long et al. 2016) and 
a trend for longer mean endometrial TLs in endometrial epithelium (Hapangama, Turner, 
Drury, Martin-Ruiz, et al. 2008). However, this preliminary evidence needs to be confirmed 
in independent studies. It is plausible that persistent proliferation and high TA of endometrial 825 
cells may interfere with the embryo implantation and trophoblastic invasion, all of which are 
known to be involved in the establishment of early pregnancy. The question of why TA is 
down-regulated in the endometrium of successful pregnancies but not so in unsuccessful 
cases implies a difference in telomerase regulation. So far, the underlying mechanisms for the 
differential (dys)regulation is not understood.  In a further case controlled study, infertile 830 
women with deep infiltrating endometriosis also had high endometrial telomerase expression 
further suggesting a detrimental effect of high levels of TA on conception/embryo 
implantation (Mafra et al. 2014). Progesterone is commonly employed to treat women with a 
variety of reproductive failures; from infertility, luteal phase defects to recurrent 
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miscarriages, yet the available evidence on the effectiveness of this therapy is inconclusive 835 
(Coomarasamy et al. 2016). Most of these conditions are multifactorial and the lesions from 
women included in clinical trials therefore are heterogeneous. This prevents elucidation of 
the true effectiveness of progesterone treatment in subgroups of women with apparently 
similar clinical manifestation. Further examination of downstream effectors of progesterone 
treatment such as telomerase may enable the stratification of women in the future in order to 840 
identify those who may benefit from the administration of the hormone.    
Polycystic Ovarian Syndrome (PCOS) 
PCOS is a common gynaecological condition defined by the clinical manifestations of 
hormonal aberrations of hyperandrogenism and insulin resistance (Clark et al. 2014; Lizneva 
et al. 2016). It is often associated with anovulation and subsequently increased risk of 845 
endometrial hyperplasia with risk of progression to endometrial cancer (Hapangama, Kamal, 
and Bulmer 2015; Hapangama and Bulmer 2016; Kamal, Tempest, et al. 2016). A genome-
wide association study in Korean women with PCOS has identified susceptibility loci for 
polycystic ovarian syndrome (Lee, Oh, et al. 2015). The authors reported the strongest signal 
to be located upstream of KH domain containing, RNA binding, signal transduction 850 
associated 3 (KHDRBS3). KHDRBS3 was found to regulate TA in colon cancer cells (Zhang 
et al. 2006). With this evidence, the authors concluded that telomerase may be an important 
driving force in developing PCOS and related phenotypes (Lee, Oh, et al. 2015). Considering 
the suggested role that unopposed estrogen and excessive androgens have on TA (Boggess et 
al. 2006) (Nourbakhsh et al. 2010) and cellular proliferation in various  carcinoma cells 855 
including endometrial cancer cells (Chao et al. 2013; Dumesic and Lobo 2013; Hapangama 
and Bulmer 2016; Kamal, Tempest, et al. 2016; Plaza-Parrochia et al. 2014), studies 
examining the involvement of telomerase in the endometrium of women with PCOS may 
unravel novel avenues for therapeutic manipulation. 
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Malignant conditions of the endometrium  860 
Constitutively high levels of hTERT expression and TA have been identified in over 90% of 
human cancers including hepatocellular carcinoma, colorectal cancer and endometrial cancer 
(Saini et al. 2009; Bertorelle et al. 2014; Lehner et al. 2002). High levels of TA in tumour 
cells contribute to increased cell proliferation, cellular immortality, carcinogenesis and cancer 
progression, while activity of telomerase and hTERT expression are usually suppressed in 865 
most human somatic tissues (Cong, Wen, and Bacchetti 1999). The involvement of 
telomerase in cellular immortality is further highlighted by the fact that most cell lines, 
including the first ever “immortal cell line”, cervical HeLa cells express very high levels of 
TA (Pandita et al. 1997). The involvement and activation of telomerase and telomere 
maintenance during tumorigenesis has been intensely studied over the years. In HeLa cells as 870 
in many cervical cancers the mechanism of telomerase activation is regulated by specific 
proteins from human papilloma virus (HPV) types 16 and 18 (Kyo et al. 1996; Sakamoto et 
al. 2000; James, Lee, and Klingelhutz 2006). Other cancers that do not involve viral infection 
in the pathogenesis also demonstrate high TA but the exact mechanism of their telomerase 
activation is not fully understood. Telomerase suppressing mechanisms that are downstream 875 
of hTERT transcription and mRNA splicing are present in rapidly proliferating embryonic 
tissue (Ulaner et al. 2000), but these are lost during neoplastic transformation (Ulaner et al. 
2000). Therefore, the tight physiological mechanisms of telomerase regulation do not exist in 
cancer cells where TA levels remain constitutively high. 
There are reports of shorter or longer TLs in different cancer cells compared with their 880 
benign counterparts. Short TLs in cancer cells may result from excessive cell proliferation 
prior to telomere stabilisation (with TA or an alternative telomere maintenance mechanism 
(ALT)). Telomere attrition can result in genomic instability which can subsequently initiate 
carcinogenesis. Absolute TL is therefore not relevant for cancer cells as long as telomeres are 
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sufficiently maintained in a capped state in order to supply the cells with an indefinite 885 
proliferation capacity. There are at least 4 activating mutations reported in TERT, POT1, 
TPP1 and TERF2IP (RAP1) genes of the telomerase and telomere complexes which can 
result in longer TLs while several other telomere and telomerase associated gene mutations 
(including repressor mutations in POT1 and activating mutations of TRF1/2) result in short 
TL (reviewed in (Mengual Gomez DL 2016)).  Since either lengthening or shortening of 890 
telomeres can result in abnormal cell proliferation or genomic instability, they can be 
implicated in carcinogenesis (reviewed in (Mengual Gomez DL 2016; Holysz et al. 2013; 
Shay 2016)).  In this review we examine the available evidence for specific aberrations in 
telomeres/telomerase in the pre-malignant and malignant conditions of the endometrium.  
Endometrial Hyperplasia 895 
Endometrial hyperplasia (EH) is characterised by irregular proliferation of endometrial 
glands that may precede or co-exist with endometrial carcinoma (Hapangama and Bulmer 
2016; Kamal, Tempest, et al. 2016). Hyperplastic glands show extremely high proliferative 
indices in comparison to either stromal cells or normal glands during the proliferative phase 
(Dallenbach-Hellweg 2010). EH is almost always due to exposure to high estrogen level and, 900 
typically accompanied with a chronic insufficiency of progesterone. Classical causes 
therefore include corpus luteum insufficiency/anovulatory cycles, PCOS, obesity with 
metabolic syndrome (extra-ovarian aromatisation of androgens), and inappropriate 
postmenopausal hormone therapy (tamoxifen, insufficient dosage of 
progestagens)(Hapangama and Bulmer 2016; Kamal, Tempest, et al. 2016).  905 
High TA levels were detected in EH, including the simple, complex and complex with atypia 
subtypes (Shroyer et al. 1997). It was also suggested that TA could be a useful diagnostic tool 
to screen postmenopausal women with endometrial premalignant and malignant lesions 
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(Maida et al. 2002). However, there is a considerable proportion of EH samples included in 
these studies that lack TA (Shroyer et al. 1997) and the absence of detectable TA did not have 910 
a specific negative predictive value (Shroyer et al. 1997). Considering the method used to 
sample the endometrium (for example, an outpatient endometrial biopsy typically samples 
approximately 4% of the uterine cavity), it is unlikely that a small area of EH is reliably 
sampled and detected with this approach. Furthermore, since TA is a feature of normal 
proliferating endometrial cells, including simple hyperplasia, the level of TA is unlikely to be 915 
a sufficient discriminator to detect malignant or pre-malignant conditions of the human 
endometrium.     
Endometrial cancer (EC) 
Most previous research on endometrial telomerase had been focussed on EC that is associated 
with high TA. EC is the commonest gynaecological malignancy and is an estrogen driven 920 
disease (Kamal, Tempest, et al. 2016). The risk factors for EC include advanced age, obesity, 
and exposure to unopposed estrogen (or progesterone deficiency). It is of interest that despite 
the high estrogenic milieu associated with the premenopausal period where most vigorous 
proliferative and regenerative activity takes place in the endometrium, carcinogenesis 
commonly occurs in the relatively quiescent, hypo-estrogenic postmenopausal period 925 
(Kamal, Tempest, et al. 2016; Hapangama and Bulmer 2016).  
Very low but detectable TA levels are reported in the postmenopausal endometrium (Tanaka 
et al. 1998). Estrogen induces telomerase in a dose dependent manner (Kyo et al. 1999). 
Various risk factors (such as obesity) for EC will marginally increase the weak estrogen 
(estrone) levels in the postmenopausal endometrium (reviewed in (Kamal, Tempest, et al. 930 
2016)). Intermittent and low levels of estrogen associated with these conditions (Kamal, 
Tempest, et al. 2016) may be sufficient for inducing low TA levels to initiate epithelial 
40 
 
proliferation in the postmenopausal endometrial cells. Furthermore, both obesity and ageing 
are chronic inflammatory conditions that are associated with oxidative stress, thus  
accelerating telomere shortening in proliferating cells (von Zglinicki et al. 1995; von 935 
Zglinicki 2000; Kamal, Tempest, et al. 2016). Therefore the most likely mechanism to 
explain EC associated telomere aberrations is the insufficient TA/ short-TL/ damaged 
telomeres theory. We propose that the hypo-estrogenic hormonal maelstrom in high risk 
postmenopausal endometrium may be associated with a potentially deficient amount of TA 
that is insufficient to maintain the short endometrial TLs and their integrity during cell 940 
division. Therefore, the ongoing proliferation in postmenopausal epithelial cells with short 
TLs may render them vulnerable to subsequent genetic instability and carcinogenic 
transformation similar to various other cancer types (Bertorelle et al. 2014; Greider and 
Blackburn 1996; Meena, Rudolph, and Gunes 2015). In line with the above hypothesis, short 
TLs have been reported in most sporadic ECs.  945 
Lynch syndrome is an autosomal dominant condition characterised by germline mutation in 
DNA mismatch repair genes resulting in increased risk of developing a variety of cancers 
including EC. Long telomeres were associated with familial cancer syndromes such as 
familial melanoma (Horn et al. 2013; Akbay et al. 2008). However, short TLs and hTERT 
gene polymorphisms predicted initiation of EC in Lynch patients (Segui et al 2013)..  950 
High TA, hTERT and hTERC expression as well as high hTERT protein levels have been 
described by many groups in ECs (Kyo et al. 1996; Saito et al. 1997; Ebina et al. 1999; 
Maida et al. 2002) . Some preliminary data in a very small patient population also suggests 
that hTERT mRNA in PBMCs can be used to diagnose early micro-metastases of EC (Liang 
et al. 2016). This observation needs further validation in an appropriately powered study. 955 
Frequent PTEN mutations and P53 loss known to occur in ECs could be associated with 
telomerase up-regulation but the exact mechanism through which these different events 
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interact is not yet clear (Zhou et al. 2006; Akbay et al. 2013). Further recent work also 
showed hTERT to be involved in epithelial mesenchymal transition (EMT), cell motility and 
metabolism, which are processes associated with cancer metastasis (reviewed in (Saretzki 960 
2014)). In a mouse model simultaneous deletion of p53 and POT1 resulted in precursor 
lesions of endometrial epithelium and induced ECs with non-endometrioid, type II 
phenotype; suggesting that telomeric instability has a critical role to play in type II ECs 
(Akbay et al. 2013). TERT promoter mutations seem to be rare in ECs (Wu et al. 2014), 
except for the clear cell (type II EC) subtype (Huang et al. 2015). Activating TERT promotor 965 
mutations are a feature of cancers derived from tissues with low relative cellular turnover 
such as the brain, therefore such mutations are not expected in the highly regenerative 
endometrial epithelium (Killela et al. 2013; Shay 2016).   
There are limited reports suggesting that the ALT pathway may be active in some 
endometrial carcino-sarcomas or uterine sarcomas (Lee, Park, and Lee 2012), but its 970 
prevalence in endometrioid ECs appears to be low (Heaphy et al. 2011). Further studies are 
required to dissect out the exact function high TA plays in ECs and how telomerase 
regulation in the postmenopausal endometrium may induce carcinogenesis, particularly, in 
the context of the high risk hormonal environment present. In the light of many reported 
alterations in the components of the telomere complex, telomerase holoenzyme and their 975 
associated proteins in cancer (Greider and Blackburn 1996; Shay 2016) in addition to the 
complex interactions of these changes with numerous tumour suppressor proteins and 
oncogenes, more detailed studies are required to fully understand the role of alterations in 
telomere maintenance pathways particular to all subtypes of EC.   
Future directions and wider implications of interventions into 980 
telomerase biology 
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hTERT has been reported to be up-regulated by various pharmaceutical and metabolic agents 
such as ACE inhibitors (Donnini et al. 2010), essential fatty acids (Das 2008), beta blockers 
(Wang et al. 2011) and calcium channel blockers (Hayashi et al. 2014) in a variety of tissue 
types. Telomerase inhibition has been reported as an off-target effect of various 985 
chemotherapeutic agents, however this it could be a secondary effect to apoptosis or 
senescence induction (Saretzki 2010). Imetelstat is the only clinically applicable synthetic 
telomerase inhibitor, which is a lipid based conjugate of the oligonucleotide GRN163 that 
binds with high affinity to the hTERC component of telomerase (Roth, Harley, and 
Baerlocher 2010; Salloum et al. 2016). Imetelstat had shown promising pre-clinical 990 
telomerase inhibitory activity across a wide range of cancer types (Roth, Harley, and 
Baerlocher 2010). However, despite high expectations, all reported data on its clinical 
effectiveness in at least 6 different clinical cancer trials have been disappointing (Salloum et 
al. 2016) with treatment resulting in significant side effects such as myelo-suppression. 
Findings from a recent small clinical pilot study demonstrate a possible specific beneficial 995 
effect of Imetelstat in clinical outcomes in myelo-proliferative conditions that needs to be 
further confirmed in larger trials (Baerlocher, Burington, and Snyder 2015). The side effect 
profile of this drug however, precludes its use in benign endometrial conditions. The 
examination of different compounds with off target inhibitory effects on TA and a more 
favourable side effect profile is required before clinical application in endometrial disease.    1000 
Our understanding of telomerase and telomere biology is rapidly expanding with many 
groups working towards developing this exciting field, as telomeres and telomerase pertain to 
a diverse range of cellular functions and processes. In addition, telomerase regulation and 
function in the human endometrium appears to be unique. The majority of treatments we 
have available at present for common benign and chronic diseases of the endometrium such 1005 
as heavy menstrual bleeding, infertility, polyps, endometriosis and endometrial hyperplasia 
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are directed towards terminally differentiated endometrial cells of the endometrial 
functionalis. The functionalis is shed each month with menstruation, thus requiring 
continuous therapy for each new functionalis layer that is regenerated. Most currently 
available therapeutic options therefore include ovarian or other hormonal analogues to 1010 
manipulate the ovarian cycle resulting in considerable side effects. Since telomerase appears 
to be involved in almost all endometrial pathologies, it provides a distinctive route to 
formulate possible curative (involving stem cells), non-hormonal therapies to treat them. 
Furthermore, current understanding of telomere and telomerase biology in ECs is far from 
comprehensive and the fact that high TA is present in normal proliferating endometrial cells 1015 
makes it difficult to extrapolate the data from other cancers to ECs. TA in normal 
endometrium has strict physiological regulation, mainly by hormones. During tumourigenesis 
this regulation becomes dysfunctional, supplying cells with a constitutively high amount of 
TA, conferring a selective advantage and a high proliferative capacity. In addition, 
telomerase and telomere biology of the endometrial cells may be modified by the cellular 1020 
interactions in a new environment (e.g. endometriotic lesions growing in the peritoneal 
cavity). A better understanding of these processes may facilitate formulating new 
interventions. Further studies in this field for both benign and malignant diseases of the 
endometrium should therefore focus on understanding the precise regulation mechanisms for 
telomerase which could potentially reveal novel targets for new treatment strategies based on 1025 
telomerase in endometrial disease. 
 
Conclusion 
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We are only beginning to understand the central role of telomeres and telomerase in the 
biology of the endometrium. Since telomerase is pivotal to endometrial regeneration, further 1030 
studies elucidating the involvement of telomere and telomerase associated proteins and their 
regulation in normal endometrial regeneration, and in endometrial pathologies will help to 
develop novel treatment strategies that are not only non-hormonal but potentially curative. 
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Figure Legends 
Figure 1. Schematic illustration of the main telomerase subunits and their interaction 1790 
with the telomere complex 
Fig 1A. Illustration of the human telomere complex and telomerase (only one half of the 
dimeric holoenzyme complex is shown for clarity). Out of the shelterin proteins, Telomere 
repeat binding factors 1 (TRF1), and 2 (TRF2) bind directly to the double-stranded telomeric 
sequence, and protection of telomeres protein-1 (POT1) binds the single-stranded overhang 1795 
hence are named telomere binding proteins and interact with remaining shelterin proteins 
TIN2 (binds to TRF1), RAP1 (binds to TRF2) and TPP1 (binds to POT1).   
Fig 1B. The four functional domains of hTERT: the telomerase N-terminal (TEN) domain has 
roles in recruiting telomerase to telomeres as well as telomeric repeat synthesis, TERC-
binding domain (TBD) interacts with hTERC, and both the reverse transcriptase (RT) domain 1800 
and C-terminal extension (CTE) contribute to the reverse transcriptase enzyme activity 
(Blackburn and Collins 2011; Nakamura et al. 1997).  
Fig 1C. Diagram of the core elements of hTERC; 5’ region containing (A) the pseudoknot 
domain and (B) stem terminus element-loop that contains the 11 nucleotide RNA template 
and (C) the template boundary element (Theimer and Feigon 2006). Both A & B domains are 1805 
important for in vivo stability of hTERC and they interact with hTERT. The RNA stabilising 
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3’ region contains (D) an H/ACA motif which interacts with dyskerin or any of the four 
H/ACA RNP components, and (E) trans-activating domain containing CR4/5C that also binds 
hTERT (Webb and Zakian 2016). The template boundary element together with the 3’ end 
prevents DNA synthesis beyond the template (Feng et al. 1995; Fu and Collins 2003; Kiss, 1810 
Fayet-Lebaron, and Jady 2010). 
 
Figure 2. Correlation of typical ovarian hormonal changes with the observed changes in 
endometrial telomerase activity, mean telomere length and endometrial  hTERT protein 
expression 1815 
A. Estrogen and Progesterone (ovarian hormones) show typical cyclical variations during the 
menstrual cycle in premenopausal women.  
B. Endometrial TA levels increase steadily under the influence of estrogen in the proliferative 
phase, whereas the levels plummet in the progesterone dominant secretory phase of the cycle 
(Kyo et al. 1997; Saito et al. 1997; Williams et al. 2001; Hapangama et al. 2009; Hapangama, 1820 
Turner, Drury, Quenby, et al. 2008).  
C. Our recent work further demonstrates that similar dynamic changes in the mean 
endometrial TLs across the menstrual cycle (Valentijn et al. 2015).  
D. In full thickness endometrial tissue sections, hTERT protein expression studied with 
immunohistochemistry employing a monoclonal mouse anti-human telomerase antibody 1825 
(ab27573, Abcam, Cambridge UK), detection with ImmPRESS anti-mouse/rabbit polymer 
and visualization with ImmPACT DAB (Vector Laboratories, Peterborough, UK). Positive 
hTERT staining was observed in functionalis and basalis epithelial cells in the proliferative 
phase but the brown positive staining is limited to the basalis epithelium in the secretory 
phase. Magnification X200, Scale bar 10μm. 1830 
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Figure 3; 
Telomere lengths and telomerase activity in the human endometrium.  
A. Endometrial TA (measured by TRAP assay) with endometrial TL (measured by qPCR) 
during the proliferative and the secretory phase of the cycle in healthy women with proven 1835 
fertility (Valentijn et al 2015).  
B. TA correlated negatively with TL in isolated epithelial cells in the proliferative phase (n= 
5, r =-0.994, ***P = 0.0005);  
C.  TA correlated positively with TL in endometrial stromal cells in the secretory phase (n = 
5, r = +0.974, ***P = 0.0005); no correlation was seen between these parameters during the 1840 
proliferative phase in the stroma or the secretory phase of the epithelium. Epithelia represent 
Epcam+ epithelial fraction (positive selection) and stroma represents Epcam- stromal cell 
fraction from the dissociated endometrial biopsies /single cell suspension were purified using 
Epcam microbeads  (negative selection). (Valentijn et al 2015).  
(D) Telomeres identified in an endometrial sample during the proliferative phase by 1845 
fluorescence in situ hybridization (FISH) using a peptide nucleic acid (PNA) telomere probe 
(Panagene, Japan). Note the brighter (red) telomere signal in the stromal cells compared to 
the epithelial cells. Scale bar 50µM 
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Figure 4 1850 
Telomerase is suggested to play a key role in our proposed model for the pathogenesis of 
endometriosis:  
(1) Ectopic endometriotic deposits are initiated by an increase in retrograde menstruation or 
an increased activity in genes that promote angiogenesis and adhesion. (2) The ectopic 
endometriotic deposits induce a local inflammatory response and secrete various cytokines. 1855 
(3) The cytokines (or other substances) act on the eutopic endometrium to induce the pro-
proliferative markers. (4) The induced eutopic endometrial cells express telomerase and adopt 
the pro-proliferative, apoptosis-resistant phenotype, which has a survival advantage in the 
peritoneal cavity. (5) Finally, retrograde menstruation of induced eutopic endometrium with 
the pro-proliferative phenotype together with other genes that also promote cell survival gives 1860 
rise to further endometriotic deposits and maintains the disease. Adapted from (Hapangama 
et al. 2010). 
 
